肥胖子痫前期女性硫酸镁替代给药方案的随机对照试验
本研究纳入37例BMI≥35的子痫前期女性,随机接受Zuspan方案(4g负荷+1g/h维持)或替代方案(6g负荷+2g/h维持)。主要结局为给药4小时后亚治疗浓度(<4.8 mg/dL)的比例。结果显示替代方案更可靠地达到治疗浓度,Zuspan组100%亚治疗浓度,替代组63%,差异有统计学意义(P=.01)。
要点
- 肥胖子痫前期女性使用Zuspan方案4小时后全部未达治疗浓度(<4.8 mg/dL)。
- 替代方案(6g负荷+2g/h维持)4小时平均血镁浓度更高(4.41 vs 3.53 mg/dL)。
- 替代方案可更可靠地达到治疗性血镁浓度,或可考虑用于肥胖患者。
核心结论
- 对于BMI≥35的子痫前期女性,6g静脉负荷后2g/h维持的替代方案比Zuspan方案更可靠地达到治疗性血清镁浓度(至少4.8 mg/dL)。
研究设计与样本
- 随机对照试验,纳入37例BMI≥35的子痫前期女性,18例接受Zuspan方案(4g负荷+1g/h维持),19例接受替代方案(6g负荷+2g/h维持)。
- 主要结局为给药4小时后亚治疗血清镁浓度(<4.8 mg/dL)的比例,计划每组18例。
主要发现
- Zuspan组4小时亚治疗浓度比例为100%(95%CI 59-100),替代组为63%(95%CI 41-81),P=.01。
- 4小时平均血清镁浓度:Zuspan组3.53 mg/dL±0.3,替代组4.41±0.5,P<.01。
关键数值与推荐
- 亚治疗血清镁浓度定义为低于4.8 mg/dL。
- Zuspan方案:4g静脉负荷,随后1g/h infusion;替代方案:6g静脉负荷,随后2g/h infusion。
临床怎么用
- 对于BMI≥35的子痫前期女性,可考虑使用6g负荷+2g/h维持的硫酸镁方案以更快达到治疗浓度。
- 需注意监测血清镁浓度,尤其在使用Zuspan方案时4小时可能仍低于治疗阈值。
局限性
- 样本量较小(共37例),可能影响结果的精确性。
- 研究仅纳入BMI≥35的子痫前期女性,结论不能外推至其他人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether obese women need greater doses of magnesium sulfate to obtain therapeutic serum concentrations for eclamptic seizure prevention. METHODS: Women with preeclampsia and a body mass index (BMI) of 35 or higher were randomly allocated to either the Zuspan regimen of magnesium sulfate (4-g intravenous [IV] loading dose, then a 1-g/h infusion) or to alternate dosing (6-g IV loading dose, then a 2-g/h infusion). Women had serum magnesium concentrations obtained at baseline, as well as after administration of magnesium sulfate at 1 hour, 4 hours, and delivery. The primary outcome was the proportion of women who had subtherapeutic serum magnesium concentrations (less than 4.8 mg/dL) 4 hours after administration. A sample size of 18 women per group was planned to compare the proportion of women with subtherapeutic serum magnesium concentrations in each group. RESULTS: From July 12, 2016, to March 14, 2019, 89 women with preeclampsia were screened and 37 were enrolled: 18 to the Zuspan regimen and 19 to the alternate regimen. A significantly greater proportion of women administered the Zuspan regimen had subtherapeutic serum magnesium concentrations at 4 hours (100% [95% CI 59-100] vs 63% [95% CI 41-81]; P=.01) compared with women administered the alternate higher dose regimen. At 4 hours, mean concentrations were significantly higher in the alternate regimen group (3.53 mg/dL±0.3 [Zuspan regimen] vs 4.41±0.5 [alternate regimen]; P<.01). CONCLUSION: The alternate dosing regimen of a 6-g IV loading dose followed by a 2-g/h IV maintenance dose more reliably achieves therapeutic serum magnesium concentrations (as defined by a concentration of at least 4.8 mg/dL) in obese women with preeclampsia. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02835339.
引用
- Brookfield KF, Tuel K, Rincon M, et al. Alternate Dosing Protocol for Magnesium Sulfate in Obese Women With Preeclampsia: A Randomized Controlled Trial. Obstet Gynecol. 2020. PMID: 33156201. doi:10.1097/AOG.0000000000004137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。